Abbott settlement and Kendamil case add to formula industry scrutiny
Abbott Nutrition agreed to pay $670 million to resolve claims related to its preterm infant formulas, without admitting liability. The settlement includes a Missouri case where a jury awarded $495 million to a plaintiff. Abbott maintains its products are safe and supported by medical professionals. Separately, Abbott challenged competitor Kendamil's advertising claims, with NAD recommending Kendamil remove certain claims about nutritional benefits.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the disclosed $670 million settlement tied to NEC allegations, which can affect perceived legal exposure and sentiment around infant nutrition. The Kendamil advertising challenge adds reputational and marketing-claims risk for the competitor, but the article does not provide a direct financial penalty or immediate trading catalyst for Kendamil’s US-listed entity.
Market read
A large NEC settlement for Abbott is the primary tradable catalyst, while the Kendamil advertising case supports the broader theme of tightening scrutiny on infant formula safety and marketing claims.
What to watch
Future price impact may hinge on whether FDA testing under Operation Stork Speed and Closer to Zero Initiative leads to new enforcement actions or standards, not just litigation settlements.
Background
The piece ties Abbott’s NEC settlement to broader infant formula safety events, including recalls, shortages, and FDA initiatives (Operation Stork Speed, Closer to Zero) plus ongoing advertising substantiation disputes.
Ticker impact
Abbott agreed to pay about $670 million to settle preterm infant formula NEC claims without admitting liability, following a Missouri verdict.
Near-term downside bias on any litigation-related headlines; longer-term impact depends on whether additional claims consolidate or expand.
The article discloses a large, concrete settlement amount tied to NEC allegations, plus continued emphasis on no reliable evidence of causation, which typically does not eliminate future claim risk.
Market effects
Reinforces heightened regulatory and litigation scrutiny across infant formula, potentially raising compliance and recall/test costs for peers.
US-focused, but could influence global infant formula brand marketing and substantiation standards.
Could spill into other markets’ advertising and safety frameworks as regulators and watchdogs reference US enforcement and testing initiatives.
Counterpoint
The settlement is framed as a compromise with no admission of liability, and Abbott highlights lack of reliable evidence linking its products to NEC, which may limit incremental downside if claims are largely resolved.
Key entities
- companyAbbott Laboratories
Agreed to pay about $670 million to resolve NEC-related preterm formula claims without admitting liability.
- companyKendal Nutricare Limited
Subject of a BBB National Programs National Advertising Division recommendation to remove or clarify certain whole-milk and comparative nutritional claims.
- regulatorFDA
Implemented expanded infant formula testing and recall communication initiatives referenced as part of ongoing oversight.
